Imagene’s Post

miRNAs play an important role in the microenvironment of HCC by changing immune phenotypes, hypoxic conditions, and acidification, as well as angiogenesis and extracellular matrix components. Moreover, changes in miRNA levels in HCC can effectively resist cancer cells to chemotherapy by affecting various cellular processes such as autophagy, apoptosis, and membrane transporter activity. In the current work, we narratively reviewed the role of miRNAs in HCC, with a special focus on tumor microenvironment and drug resistance. link: https://lnkd.in/dzPFW__4

G-proteins, integral in GPCR signaling, emerge as promising therapeutic targets, especially in cancer. SignalChem Biotech Inc. leads in providing active GTPases, inactive mutants of G-proteins, and GAPs/GEFs. SCB employs rigorous activity assay protocols, verifying the specific activities and assessing the purity of its G-proteins. Explore the potential of G-proteins in drug discovery for cancer and cardiovascular disorders. See our selection of recombinant G-proteins: https://ow.ly/13PH50Qqvtq #GProteins #CancerResearch #DrugDiscovery

🔎 PROTEINA Case Study: Unveiling BCL2 PPI network 🔬 Discover our approach to investigating BCL2 PPI biomarkers to reveal the therapeutic impact of Venetoclax, the first FDA-approved BCL2 inhibitor, in transforming the treatment of hematologic malignancies. 📣 Takeaway: Assessing the efficacy of anti-cancer treatment has been always a primary objective for cancer drug developers. Our innovative SPID platform allows in-depth analysis of 47 distinct metrics including 20 different protein-protein interactions within the BCL2 family, providing a thorough quantitative assessment of apoptosis signaling from clinical samples of patients undergoing treatment. Check out the poster below to find out more about PROTEINA’s discovery, presented by our chief scientist, Byoungsan Choi at #AACR2024. Read a full abstract by clicking here: https://lnkd.in/gcJ7knrr   #PROTEINA #SPIDPlatform #CaseStudy #PPIBiomarker #BCL2Inhibitor #BCL2Family #MultipleMyeloma #Venetoclax  

Our well-characterized syngeneic models consist of a fully functional immune system making them the ideal choice to evaluate your novel immuno-oncology agents as well as combination therapies. Syngeneic models are predictive models for cost effective immunotherapy evaluation, an effective tool to understand mechanisms of action, and predict response before moving to more complex and costly humanized models. We provide a large collection of syngeneic models covering a variety of cancer types and immune phenotypes, available now for your efficacy and PD studies. Learn more ➡️ https://bit.ly/49W9fZL #Syngeneic #DrugDevelopment

Please join us at #SITC2024 as we present the latest updates in our Phase 1 programs. #cancer #aiandml #immunooncology #immunotherapy #biotech #innovation

We are presenting at this year's AACR annual meeting! Meet our team to discuss how we use transcriptional reprogramming in cancer to deliver new chemical scaffolds and place drug targets in a novel clinical disease context. Date and Time: April 9, 1:30 - 5:00 PM Abstract Number: 5891 Poster Title: An image-based phenotypic screen identified the bromodomain of CBP/p300 as new cancer drug resistance target and enabled the development of the clinical candidate TT125-802 #AACR24 #StoppingCancerDrugResistance

Very interesting webinar on the latest advancements in gastric cancer biomarkers for pathologists!

Clinical trials benefit patients and divert specialty drug costs, but barriers to enrollment include access, costs and coverage, and delays from tissue genomic tumor profiling. Our study shows that patients with non–small cell lung cancer enrolling in clinical trials following liquid biopsy had improved survival without increasing costs compared with matched controls. Specialty drug management should include coverage for testing likely to guide the appropriate use of therapies, which improves survival and drives clinical trial enrollment, also improving survival. #lungcancer #lcsm https://lnkd.in/e6vAQmcM

Meet #ivonescimab, Akeso's cancer-fighting superstar! 🌟 — It just crushed the competition in a head-to-head Phase 3 clinical trial, outperforming #pembrolizumab! 🏆 💪 Ivonescimab, discovered by Akeso, is a first-in-class tetravalent PD-1/VEGF bispecific antibody engineered with Akeso's Tetrabody technology. It displays unique cooperative binding to each of its intended targets consistent with increased in vitro functional bioactivities compared with VEGF or PD-1 alone. Importantly, the Fc-null IgG1 design resulted in reduced FcgR interactions and minimal ADCC, ADCP activities consistent with its clinical immunosafety profile. 🧬 Curious about its mechanism of action? 🧬 🎥Check out this video for an in-depth look! 🎥 #bispecific #immunotherapy #IO #cancer #VEGF #science #Akeso #ivonescimab

January is Thyroid Awareness Month. Join us in spreading education about thyroid cancer, which is estimated to be diagnosed in more than 43,000 people each year¹. This infographic ², derived exclusively from NeoGenomics data, shares insights about the disease – and underscores the importance of precision medicine. Equipping physicians and pharmaceutical partners with cancer tests that enable precision medicine can unlock targeted treatment options for patients. #NeoGenomics #ThyroidAwarenessMonth #ThyroidCancer #CancerTesting Sources: 1= American Cancer Society; 2= NeoGenomics Data